Pfizer Gains Option to Acquire Gene Therapy Specialist Vivet Therapeutics
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 3 (Table of Contents)
Published: 27 Mar-2019
DOI: 10.3833/pdr.v2019.i3.2413 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Following in the footsteps of Biogen and Roche, Pfizer has acquired a 15% equity interest in gene therapy specialist, Vivet Therapeutics, with an option to acquire the company following the release of Phase I/II clinical trial data for VTX-801...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS